

Laura A Lucaciu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5415671/publications.pdf>

Version: 2024-02-01

10
papers

101
citations

1478505

6
h-index

1720034

7
g-index

11
all docs

11
docs citations

11
times ranked

77
citing authors

#	ARTICLE	IF	CITATIONS
1	Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1835-1844.e6.	4.4	26
2	Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2011-2021.	1.3	20
3	Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110640.	3.2	17
4	Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease. <i>Journal of Personalized Medicine</i> , 2021, 11, 1130.	2.5	13
5	Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? â€” a systematic review. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 669-677.	1.6	12
6	Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 67-76.	3.7	7
7	Are we addressing the top 10 research priorities in IBD?. <i>Frontline Gastroenterology</i> , 2021, 12, 564-569.	1.8	6
8	P123â€”Are we addressing the top ten research priorities in management of IBD in the UK?. , 2021, , .		0
9	P155â€”88000 faecal calprotectin measurements over 15 years: insights gained from the edinburgh faecal calprotectin register. , 2021, , .		0
10	PMO-48â€”Both single and multiple switching between infliximab biosimilars can be safe and effective in ibd. , 2021, , .		0